Pharmacologic Therapy for Pulmonary Arterial Hypertension in Adults
Autor: | Jess Mandel, Lorinda Chung, Erika B. Rosenzweig, James R. Klinger, Sandra Zelman Lewis, Joe Ornelas, Darren B. Taichman, Terence K. Trow, Stuart Rich, Harold I. Palevsky, C. Gregory Elliott, David B. Badesch, Namita Sood, Rex C. Yung |
---|---|
Rok vydání: | 2014 |
Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty business.industry Delphi method MEDLINE Guideline Cochrane Library Critical Care and Intensive Care Medicine law.invention Systematic review Pharmacotherapy Randomized controlled trial law medicine Pharmacologic therapy Cardiology and Cardiovascular Medicine Intensive care medicine business |
Zdroj: | Chest. 146:449-475 |
ISSN: | 0012-3692 |
Popis: | OBJECTIVE Choices of pharmacologic therapies for pulmonary arterial hypertension (PAH) are ideally guided by high-level evidence. The objective of this guideline is to provide clinicians advice regarding pharmacologic therapy for adult patients with PAH as informed by available evidence. METHODS This guideline was based on systematic reviews of English language evidence published between 1990 and November 2013, identified using the MEDLINE and Cochrane Library databases. The strength of available evidence was graded using the Grades of Recommendations, Assessment, Development, and Evaluation methodology. Guideline recommendations, or consensus statements when available evidence was insufficient to support recommendations, were developed using a modified Delphi technique to achieve consensus. RESULTS Available evidence is limited in its ability to support high-level recommendations. Therefore, we drafted consensus statements to address many clinical questions regarding pharmacotherapy for patients with PAH. A total of 79 recommendations or consensus statements were adopted and graded. CONCLUSIONS Clinical decisions regarding pharmacotherapy for PAH should be guided by high-level recommendations when sufficient evidence is available. Absent higher level evidence, consensus statements based upon available information must be used. Further studies are needed to address the gaps in available knowledge regarding optimal pharmacotherapy for PAH. |
Databáze: | OpenAIRE |
Externí odkaz: |